Neoadjuvant therapy is already considered as the standard of care for non-metastatic ≥ cT2 N0 TNBC, HER2+ BC and inflammatory BC based on the higher rates of clinical and pathological tumor response showing durable tumor control before surgery [24,25,28,50,52];. Here, ERBB2 is linked to breast cancer.